Evidence map›Paper›PMID 40751913›Full record

ArticleCell reports2025

Uropathogenic Escherichia coli niche occupancy determines the effects of mucosal vaccine against FimH.

Jesús M Santiago-Borges, Anne L Rosen, Ariel Hernandez-Leyva, Christopher P Tomera, Michael A Lint, Alexandra E Paharik, Vincent Vanyo, Jerome S Pinkner, Karen W Dodson, Swaine L Chen and 3 more

Abstract read
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. AbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jesús M Santiago-BorgesCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Division of Allergy and Immunology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Anne L RosenCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Division of Allergy and Immunology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Ariel Hernandez-LeyvaCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Division of Allergy and Immunology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Christopher P TomeraCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Division of Allergy and Immunology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Michael A LintCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Division of Allergy and Immunology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Alexandra E PaharikCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Division of Allergy and Immunology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Vincent VanyoCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Division of Allergy and Immunology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Jerome S PinknerCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.
Karen W DodsonCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.
Swaine L ChenInfectious Diseases Translational Research Programme, Department of Medicine, Division of Infectious Diseases, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; Laboratory of Bacterial Genomics, Genome Institute of Singapore, Singapore, Singapore.
Chyi S HsiehDivision of Rheumatology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Scott J HultgrenCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA.
Andrew L KauCenter for Women's Infectious Disease Research, Washington University in St. Louis, St. Louis, MO, USA; Division of Allergy and Immunology, Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA; Department of Molecular Microbiology, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: akau@wustl.edu.

Funding

NATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8M
TRAINING PROGRAM IN CELLULAR AND MOLECULAR BIOLOGYT32GM007067 · NIGMS · WASHINGTON UNIVERSITY · PI TRUE-KROB, HEATHER L · 1985 to 2020
$20.4M
Epidemiologic and molecular basis of the gut-urinary tract axis in urinary tract infectionR01DK121822 · NIDDK · WASHINGTON UNIVERSITY · PI Ashlee Miriam Earl, SCOTT J. HULTGREN · 2020 to 2026
$4.9M
Harnessing Antibody Responses to Prevent and Treat Urinary Tract InfectionsR01AI165915 · NIAID · WASHINGTON UNIVERSITY · PI Andrew Leon Kau · 2022 to 2026
$3.1M
Impact of gut microbial metabolism on host breath volatilesF30DK127584 · NIDDK · WASHINGTON UNIVERSITY · PI HERNANDEZ-LEYVA, ARIEL JOSE · 2021 to 2023
$91k
Doris Duke Charitable Foundation 2019083NIAID NIH HHS R01 AI165915NIDDK NIH HHS F30 DK127584NIDDK NIH HHS R01 DK121822NIGMS NIH HHS T32 GM007067NIGMS NIH HHS T32 GM007200
6 · The paper itself

Abstract

In people with urinary tract infections (UTIs), uropathogenic Escherichia coli (UPEC) often colonizes the gut, forming a reservoir and contributing to recurrent UTIs. Mucosal immunization targeting UPEC within the gut presents a promising antibiotic-sparing strategy to prevent UTIs by depleting this reservoir. The FimH adhesin that tips type 1 pili is a critical virulence factor in UTI and aids in gut colonization. Here, we assess the potential of a FimH mucosal vaccine to reduce UPEC gut colonization in mice. Our findings show that vaccine-induced depletion of an introduced UPEC strain was influenced by microbial competition from pre-established microbes. This competition partially restricted the incoming UPEC strain to the mucus, where immunization was associated with reduced FimH expression. These results demonstrate that oral FimH vaccine effectiveness relies on intra-niche competition, underscoring the complexity of host-pathogen interactions that must be considered as we refine immune tools to target gut microbes.

Indexed as

Adhesins, Escherichia coliEscherichia coli InfectionsEscherichia coli VaccinesFimbriae ProteinsUrinary Tract InfectionsUropathogenic Escherichia coliAnimalsFemaleHumansMiceMice, Inbred C57BLAdhesins, Escherichia coliEscherichia coli VaccinesFimbriae ProteinsfimH protein, E colicolonizationCP: ImmunologyCP: MicrobiologyEscherichia coliFimHfimSgastrointestinal tractgut colonizationmicrobiomemucosal vaccinationnichetype 1 piliUPECurinary tract infectionuropathogenic E. coliUTIvaccination

Identifiers

PMID40751913
PMCPMC12447472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.